

The *gastrulation defective* gene of *Drosophila melanogaster* is a member of the serine protease superfamily

(dorsal–ventral patterning/protease cascade)

KENNETH D. KONRAD*†, THOMAS J. GORALSKI†‡, ANTHONY P. MAHOWALD†‡, AND J. LAWRENCE MARSH*§

*Developmental Biology Center and the Department of Developmental and Cell Biology, University of California Irvine, Irvine, CA 92697-2300; and

‡Department of Developmental Genetics and Anatomy, Case Western Reserve, Cleveland, OH 44106

Contributed by Anthony P. Mahowald, April 3, 1998

ABSTRACT The establishment of dorsal–ventral polarity in the oocyte involves two sets of genes. One set belongs to the *gurken-torpedo* signaling pathway and affects the development of the egg chorion as well as the polarity of the embryo. The second set of genes affects only the dorsal–ventral polarity of the embryo but not the eggshell. *gastrulation defective* is one of the earliest acting of this second set of maternally required genes. We have cloned and characterized the *gastrulation defective* gene and determined that it encodes a protein structurally related to the serine protease superfamily, which also includes the Snake, Easter, and Nudel proteins. These data provide additional support for the involvement of a protease cascade in generating an asymmetric signal (i.e., asymmetric Spätzle activity) during establishment of dorsal–ventral polarity in the *Drosophila* embryo.

Dorsal–ventral polarity in the *Drosophila* embryo is specified by localized activation of a ligand, Spätzle (SPZ), that ultimately results in a ventral to dorsal gradient of *dorsal* (DL) protein in the blastoderm nuclei (1, 2). This gradient leads to differential expression of zygotic genes that specify different cell fates along the dorsal–ventral axis of the embryo. The DL nuclear gradient is established by the localized activation of the *Toll* (TL) signaling pathway (3, 4). Although the TL receptor is distributed uniformly in the plasma membrane, genes upstream of TL act to asymmetrically activate the ligand SPZ (5, 6). At least seven genes are required for correct activation of TL on the ventral side of the egg (7, 8). Loss of function mutations in these genes lead to embryos that completely lack ventral structures and are dorsalized. Among these seven, *nudel* (*ndl*), *pipe* (*pip*), and *windbeutel* (*wind*) are required in the somatic follicle cells that surround the oocyte (7, 9, 10) whereas the four remaining genes, *gastrulation defective* (*gd*), *snake* (*snk*), *easter* (*ea*), and *spz*, are required in the germ line (7, 11, 12). EA and SNK both share structural homology with extracellular, trypsin-like, serine proteases (8, 13–16). Epistasis studies suggest a pathway in which *ndl* and *gd* act immediately upstream of *snk*, *ea*, *spz*, and *tl* (15, 16). The NDL protein encodes an extracellular matrix-like molecule that may be anchored in the vitelline membrane (10). The *wind* gene encodes a protein with motifs similar to a vertebrate endoplasmic reticulum protein of unknown function (17). The *pip* gene has not been characterized molecularly.

GD is critical for generating the asymmetric presentation of SPZ. Injection of perivitelline (PV) fluid from embryos lacking both maternal and zygotic DL protein can rescue *snk* and *ea* embryos but cannot rescue *gd* embryos, indicating that GD activity is not present in the fluid whereas SNK and EA activities are (8). Ventral cuticle elements can be rescued in *gd*

mutants as well as in *snk* and *ea* embryos by injection of fluid containing SPZ. However, rescue of *gd* embryos is unique in that the polarity of the rescued embryos depends on the site of injection. This pliability of *gd* embryo polarity, the insolubility of the GD protein, and the temperature-sensitive period of *gd* function (12) suggest that *gd* may be the first of the maternally required genes, acting in concert with the somatically expressed genes (*ndl*, *pip*, *wind*) to cause the localized activation of SPZ (8, 10, 18, 19).

Here, we report the cloning and characterization of the *gd* gene. We show that GD displays significant structural similarity to trypsin-like serine proteases although there are some important differences. We propose that GD acts early to establish a localized complex involving other putative proteases EA, SNK, and NDL that leads to localized activation of SPZ.

MATERIALS AND METHODS

***Drosophila* Stocks and Mapping.** Mutations used are described in refs. 12, 20–22. Map positions were assigned based on the following: 97 of 129 recombinants between *miniature* (*m*) and *furrowed* (*fw*) occurred distal to *l(1)13* (*cacophony*) placing *cac* at 36.66; 5 of 8 recombinants between *l(1)13* and *fw* were distal to *gd*⁴, placing *gd* at 36.78; 2 of 10 *gd/fw* recombinants were distal to *twisted gastrulation* (*tsg*), placing *tsg* at 36.79. Thus, *gd* is located proximal to *cac* and distal but very close to *tsg*.

Molecular Procedures. Genomic DNA libraries (23, 24) were probed with *Eco*RI fragments isolated from a microdissection library (prepared by A.P.M., unpublished work) in the European Molecular Biology Laboratory 4 phage vector. Phage were purified and fragments subcloned for further walking by using standard methods (25). A plasmid cDNA library from 0- to 4-h-old embryos (26) was probed with a 1.3-kb *Hind*III genomic subclone that hybridized to the only RNA in the region that was expressed exclusively in females (≈23.9–25.2; Fig. 1), and the longest was sequenced.

RNA was prepared from collections of developmental stages observed to be at least 95% free of older stages and extracted as described (27). Poly(A)-containing RNA was prepared by the batch isolation method (25).

Abbreviations: SPZ, Spätzle; DL, dorsal; TL, *Toll*; NDL, *nudel*; *gd*, *gastrulation defective*; *snk*, snake; *ea*, easter; *tsg*, *twisted gastrulation*; PV, perivitelline.

Data deposition: The sequences reported in this paper have been deposited in the GenBank database (*gd* gene sequence, U09808; cDNA, AFO56311; genome, DMU09808).

†Present addresses: Department of Molecular Genetics and Cell Biology, University of Chicago, Chicago, IL 60637 (A.P.M.) and Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (K.D.K., T.J.G.).

§To whom reprint requests should be addressed. e-mail: jlmarsh@uci.edu.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.

© 1998 by The National Academy of Sciences 0027-8424/98/956819-6\$2.00/0
PNAS is available online at <http://www.pnas.org>.




FIG. 1. Correlation of the genetic and molecular maps and the transcripts of *gd* and *tsg*. The top line displays the recombination distances in centimorgans between the loci in this region (*cf. Materials and Methods*). They are depicted according to their orientation along the X chromosome with proximal to the right. The approximate locations of breakpoints for several inversions were determined by Southern blotting as follows: In A97 (51.9/49.3kb), In A101 (44.5/42.5), In N66 (38.1/36.1) and In A78 (32/27.6). The bars represent DNA that is present in the deficiency chromosomes *Df(1)HF368*, *Df(1)m13*, and *Df(1)RC29*. The lightly shaded areas represent the uncertainty of the breakpoints, and the dashes indicate the DNA which is missing. The portion of the chromosomal walk used to identify the *gd* locus is shown immediately below the breakpoints with the extent of overlapping λ phage clones 320, 348, K3, and C8 indicated in kilobases. The positions of the 9.3-kb *EcoRI* and 10.2-kb *HindIII* transformation subclones are shown expanded below the chromosome walk as is the region that was sequenced. The sequenced region abuts other sequenced regions from the *tsg* gene and beyond. A partial restriction map of the 9.3-kb *EcoRI* subclone is displayed with *E* = *EcoRI*, *H* = *HindIII*, *Bg* = *BglII*, and *B* = *BamHI*. The extent and orientation of the 2.1-kb *gd* and 1.0-kb *tsg* transcripts are shown. The smaller lightly shaded blocks indicate the primary transcripts, and the protein coding regions are shown as larger darker blocks.

Restriction endonuclease digests were performed in TA buffer (28). DNA sequencing was performed as described in the Sequenase kit of United States Biochemical. The entire *gd* cDNA and 9.4-kb genomic subclone were sequenced on both strands by primer walking. No differences were observed between the genomic and cDNA sequences other than introns. Other routine DNA manipulations were performed according to standard methods (25, 29).

In situ hybridizations were performed by using digoxigenin RNA probes prepared as described by the manufacturer (Boehringer Mannheim). Ovaries were prepared as described by Tautz and Pfeifle (30) by using a final probe concentration of ≈ 10 ng/ μ l in a 50- μ l volume at 55°C.

RESULTS

Chromosomal Location of *gd*. The *gd* locus fails to complement *Df(1)KA10*, placing it in the 11A region (12) on the X chromosome. Three other deficiencies *Df(1)HF368* (11A2-3;11B9), *Df(1)m13* (10C-D;11A3-5), and *Df(1)RC29* (11A1-4; 11A4-5) also fail to complement *cac*, *gd*, *tsg*, and *fw*, placing all four loci between polytene bands 11A2 and 11A5. The relative order of these genes was determined by recombination mapping (*cf. Materials and Methods*; Fig. 1).

Molecular cloning of *gd* and transcript identification. *EcoRI* inserts from a microdissection library were used to select genomic clones from a Canton S genomic library (23). The 11A breakpoint of *In(1)N66* (7A7-8;11A3-5) is sufficiently close to *gd* to affect its expression (12); therefore, a chromosomal walk (31) was initiated from a genomic clone (λ C8) that hybridized *in situ* both proximal to the *In(1)N66* 11A breakpoint and distal to the constriction in 11A7,8 (21). A total of 100 kb of overlapping genomic DNA fragments was isolated (21) (Fig. 1). The breakpoints of *Df(1)HF368*, *Df(1)m13*, and *Df(1)RC29*, as well as the location of inversion breakpoints that affected *gd* expression, were identified by Southern blotting (Fig. 1). This focused attention on a 33-kb region defined by the distal breakpoint of *Df(1)HF368* and the proximal breakpoint of *Df(1)RC29* (21) (Fig. 1), which corresponds to the cytogenetic location of *gd* determined above.

Phage clones spanning this 33-kb region were used to probe developmental Northern blots containing RNA from different stages of the *Drosophila* life cycle. We identified six transcripts of different sizes (1, 1.3, 1.9, 2.1, 2.8, and 4.7 kb; Fig. 2). Only the 2.1-kb transcript was found exclusively in ovaries and early embryos and thus fit the developmental profile expected for *gd* (12). To further localize these transcripts, similar RNA blots were probed with subclones across the region of highest transcript density (21). This analysis determined the following transcript order (2.1, 1, 1.3, 2.8, 1.9, and 4.7 kb) and localized the 2.1-kb *gd* candidate mRNA to a region spanning the 1.3-kb *HindIII* fragment (24-25.3) (Fig. 2). To determine whether any mutations in the *gd* locus might lead to restriction fragment length polymorphisms, Southern blots containing *HindIII* digested DNA from homozygous *gd* mutant females were probed with the DNA from the λ 348 clone. Two *gd* alleles lacked a 0.6-kb *HindIII* fragment, which is one of the two




FIG. 2. Transcript map of the *gd* region. mRNA from stages throughout the entire life cycle were probed. The results obtained with three probes are shown here (i.e., a 1.3-kb *HindIII* and 3.1-kb *BamHI* fragments and the entire K3 phage DNA). The 2.1-kb transcript seen in early embryos (0-3.5 h) and faintly in females is the only transcript in the region with a developmental pattern consistent with the genetics of *gd*. It is the only transcript detected by the 1.3-kb *HindIII* fragment. The band in females and embryos is of similar size although this result is distorted here by a curve in the migration front. The 3.1-kb *BamHI* probe hybridizes to three bands whereas the entire K3 phage hybridizes to the 2.8-, the 1.9-, and a 4.7-kb transcript. Additional probing with other subclones permitted ordering the transcripts as shown (21). The *tsg* transcript has been identified by transformation (32). The 4.7-kb transcript likely corresponds to the *furrowed* gene (Corces, V.G., Johns Hopkins Univ., personal communication). The 2.8-kb transcript appears specific to males, and the 1.9-kb transcript is specific to females. From the hybridization pattern, we infer that these are likely alternative splicing variants of a single gene. The 1.3-kb transcript may have a large splicing variant as well. We have not yet identified any genetic lesions that may correspond to these transcription units.




FIG. 4. *In situ* hybridization to *gd* mRNA in ovaries. (A) *gd* mRNA first appears in the germarium. Levels continue to build in the nurse cells and oocytes of the vitellarium. Expression also begins to appear in the follicle cells (fc) as the oocytes move into stage 10. (B) Extensive transcription in both nurse cells and in follicle cells is seen in stage 10 oocytes. In oocytes where the D/V axis can be inferred from the position of the oocyte nucleus, a rough ventral to dorsal gradient of transcript often can be detected. (D) By stage 13, residual *gd* transcripts remain in the nurse cells as well as the surrounding follicle cells. (C) Sense strand control probe shows no detectable background staining.

conserved D adjacent to the active site S is replaced by I and a short insert of amino acids immediately adjacent. There is a small acidic region N-terminal to the catalytic site, which is a feature shared by SNK but not EA.

***gd* Is Expressed in Both Follicle Cells and the Germ Line.** *In situ* hybridization using antisense riboprobes from the *gd* locus indicates that expression of *gd* begins in previtellogenic stages. *gd* mRNA is seen in the germ line-derived nurse cells of the germarium (Fig. 4A). Expression continues throughout oogenesis with transcripts from the nurse cells accumulating in the oocytes of the vitellarium (Fig. 4A). Of interest, at about stage 10, *gd* expression can be detected in the surrounding follicle cells, although the level of signal is lower than the intense signal seen in the nurse cells at that stage (Fig. 4B). In some stage 10 oocytes, accumulation of mRNA appears to be somewhat graded along the dorsal-ventral axis with marginally higher levels of mRNA in the ventral follicle cells (Fig. 4B). By stage 13, residual mRNA remains in the shrinking nurse cells and in the follicle cells surrounding the oocyte (Fig. 4D).

GD Protein Is Processed. An *EcoRV* restriction fragment from the *gd* cDNA (amino acids 347–548) was cloned in-frame into pBS SK and used to express protein. Bacterially derived protein was harvested from inclusion bodies and used as an immunogen in rabbits. Western blots of extracts from ovaries and early embryos revealed three cross reacting bands (34, 30, and 27.5 kDa) that were smaller than the 60-kDa full length protein observed in *in vitro* translation experiments (Fig. 5). These bands were not detected by the preimmune serum. Furthermore, all three peptides were completely absent in extracts from *gd*⁷ females whereas extracts of *gd*⁵ and *gd*⁶ lacked the two larger bands and *gd*⁴ possessed all three. Extracts of carefully staged embryos and ovaries showed that the cross-reacting polypeptides are most abundant in the ovaries, that the level of protein decreases from the moment of egg laying, and that it is essentially gone by 4 h (Fig. 5).

DISCUSSION

There are two sets of genes involved in establishing the dorsal-ventral polarity of the mature oocyte. The first set (reviewed in refs. 41 and 42) includes genes in the *gurken-torpedo* signaling pathway, and mutations in these genes lead to defective development of the chorion and in most instances to loss of ventrally derived pattern elements. The second set of genes (called the “dorsal group genes”) functions slightly later in development, and mutations in these genes affect only the dorsal-ventral polarity of the embryo but not the eggshell. GD is the earliest acting germ line-dependent member of the second group.

GD as a Secreted Serine Protease. Three of the dorsal group genes, SNK, EA, and NDL, are related to serine proteases. The work reported here identifies a fourth serine protease-related dorsal group protein, GD. This observation raises the possibility of a signal amplification cascade of sequential protease activation similar to that occurring in blood clotting (reviewed in ref. 43).

The *gd* protein possesses the catalytic triad (H, D, S) characteristic of serine proteases. Although the homology to serine proteases suggests a proteolytic role, several significant differences between the sequence of GD and other members of the chymotrypsin family of serine proteases suggest that GD may behave atypically. Most eukaryotic serine proteases undergo an activation process after zymogen cleavage in which the α amino group of the catalytic domain forms a salt bridge to an aspartate residue (D) located adjacent to the active site serine (44). In GD, this aspartic acid residue is replaced by isoleucine, making it unlikely that the protease could be activated via the classical mechanism. However, several bacterial members of the α -lytic endopeptidase family (e.g., subtilisin) contain residues other than D (e.g., T) adjacent to the active serine (45), and complement component C2 con-




FIG. 5. Physical characterization of the GD protein. (A) Western blot of protein extracts from OreR females and staged embryos probed with antisera raised against the GD peptide. The peptide produced by *in vitro* translation of synthetic *gd* mRNA is 60 kDa (not shown), and the peptides detected *in vivo* are smaller. (B) Western blot of protein extracts from ovaries of various *gd* mutant females suggests that some *gd* alleles affect the protein detected by this antiserum.

tains E instead of D (46). Typically, activation involves cleavage after a positively charged amino acid (R or K) followed by two branch chain amino acids and a highly conserved G. The N-terminal residue is most commonly I but may be L, V, or M (45, 47). One putative cleavage site for GD based on position relative to conserved motifs (e.g., G-WPW and CGGTSLV) is S ITRG. Although this putative site has S instead of R or K and has G in the 4th position rather than the 3rd, cleavage at this site would produce a peptide of 30.5 kDa that could possibly correspond to the 30-kDa species observed on the Western blots. The extensive heteroallelic complementation exhibited by *gd* is consistent with the possibility that the GD protein may function as a multimer (12) perhaps during an activation process.

There is precedence for unusual activating cleavage sites in other proteases. The plasminogen activator of the vampire bat is activated by cleavage between a histidine followed by serine (i.e., H⁺STGG) (48). The crab coagulation factor is cleaved at the sequence I⁺IAGG (Fig. 3). Complement factors C2 and B are cleaved by a novel mechanism between R and K (49). GD has a sequence motif beginning at amino acid 136 (i.e., R⁺K LSEIPDKKSSLLLD. . .) that resembles the complement B cleavage region (underlined residues). However, cleavage at this R⁺K site would produce a 43-kDa protein, which we do not observe on Western blots. Additional processing events that may further reduce the size make the potential use of this site difficult to analyze. An alternative is that GD is not activated by cleavage. The rhesus monkey apolipoprotein is inactive as a protease, lacking the active site S. Human apolipoprotein contains the complete H-D-S triad, but activation apparently would require cleavage of an S-I bond. Thus far, no proteolytic activity associated with human apolipoprotein has been reported. Other examples of inactive serine proteases containing a complete triad include mouse α -NGF (50) and bovine procarboxypeptidase A subunit in which the lack of proteolytic activity has been attributed to the absence of two N-terminal hydrophobic residues (45, 47). Thus, one possibility is that GD cannot undergo an activating cleavage and consequently does not show proteolytic activity, perhaps like α -NGF or procarboxypeptidase. An alternative possibility is that GD is indeed

proteolytically active but undergoes an atypical activation event and apparently other processing events, yielding three different polypeptides. In either case, it appears unlikely that GD is activated by a standard mechanism.

GD Is Central to Establishing Asymmetric Signaling of Toll. The dorsal-ventral asymmetry of the embryo is established by a signal that is transmitted through the uniformly distributed TL receptor, resulting in a graded relocation of DL into the nuclei of the blastoderm embryo (3, 4). Injection experiments involving the use of dominant active EA (15) and SNK (16), as well as injection of PV from *dl* embryos into *gd* mutant embryos, lead to production of ventral elements at the site of injection rather than in the normal ventral region (8). These data suggest that D/V polarity is established by asymmetric presentation of the TL ligand to the oocyte. PV fluid from *dl* embryos (thought to be depleted of SPZ ligand because of the presence of the TL receptor) can rescue D/V polarity in *snk* and *ea* embryos. This same PV fluid cannot restore normal ventral structures to either *gd* or *ndl* embryos. In contrast, injection of PV fluid from *Tl* mutant embryos (thought to contain active SPZ ligand) into *gd* embryos produces ventral structures at the site of injection (8). The same fluid injected into *snk* or *ea* embryos produces embryos with normal polarity independent of the site of injection (8). This result strongly suggests that GD is a key component required for establishing the localized activation of SPZ and thus the asymmetric activation of TL. Because the temperature-sensitive period for both NDL and GD action includes a period before fertilization when the initial D/V asymmetry is known to be established (12), it is possible that these two gene products cooperate to form a localized anchor for a SPZ activating complex.

EA and SNK both share significant structural homology with extracellular trypsin-like serine proteases (13, 14). Experiments using dominant active forms of SNK and EA show that SNK activates EA, which in turn activates the SPZ ligand. In combination with the somatically expressed genes, *wind*, *pip*, and *ndl*, GD activates SNK in a location-dependent manner that marks the future ventral cells (15, 51). The recent cloning of *ndl* indicates that NDL is a large (\approx 350 kDa) extracellular glyco-protein with motifs suggesting that it might bind to extracellular matrix as well as to other proteins. NDL also contains a serine protease catalytic domain (10). The occurrence of several protease-like proteins both upstream (NDL) and downstream (SNK; EA) of GD may be responsible for the multiply processed GD peptides observed on Western blots. The physical location of the NDL protein (including whether it is incorporated as a component of the vitelline membrane) is not yet known, although the fragility of the *ndl* embryos suggests that NDL may be required for stability of the vitelline membrane (10). *gd* mRNA is expressed in follicle cells beginning at about stage 10 and may be graded in a ventral to dorsal manner, although it is expressed uniformly in the nurse cell/oocyte complex. The location of GD remains to be determined.

Four of the five currently identified genes needed for asymmetric activation of the SPZ ligand encode secreted members of the serine protease superfamily. We propose that GD functions as part of an anchored complex that triggers a proteolytic activation hierarchy involving NDL, SNK, and EA, resulting in localized activation of SPZ ligand and asymmetry along the D/V axis.

We fondly acknowledge the work and assistance of the late George Lefevre whose extensive genetic characterization of this region provided the foundation for this study. We are indebted to R. DeLotto for sharing his unpublished results and for fruitful discussions, to R. Bradshaw for informative discussions about proteases, and to H. Theisen and K. Arora for comments on the manuscript. We gratefully acknowledge the support of National Science Foundation Grants

DC8615701 to K.D.K. and J.L.M. and DCB8904047 to K.D.K. and National Institutes of Health Grants GM28972 and PO1 HD27173 to J.L.M. and HD17607 to A.P.M. A.P.M. acknowledges the assistance of Dr. Jan-Erik Edström and the European Molecular Biology Organization course at the European Molecular Biology Laboratory where the microdissection of region 11A was accomplished. We gratefully acknowledge the computational support of GenBank, the University of California Irvine office of academic computing, and the resources of the National *Drosophila* Stock Center in Bloomington, IN.

1. Morisato, D. & Anderson, K. V. (1995) *Annu. Rev. Genet.* **29**, 371–399.
2. Ray, R. P. & Schupbach, T. (1996) *Genes Dev.* **10**, 1711–1723.
3. Hashimoto, C., Hudson, K. L. & Anderson, K. V. (1988) *Cell* **52**, 269–279.
4. Hashimoto, C., Gerttula, S. & Anderson, K. V. (1991) *Development (Cambridge, U.K.)* **111**, 1021–1028.
5. Morisato, D. & Anderson, K. V. (1994) *Cell* **76**, 677–688.
6. Schneider, D. S., Jin, Y., Morisato, D. & Anderson, K. V. (1994) *Development (Cambridge, U.K.)* **120**, 1243–1250.
7. Stein, D., Roth, S., Vogelsang, E. & Nüsslein-Volhard, C. (1991) *Cell* **65**, 725–735.
8. Stein, D. & Nüsslein-Volhard, C. (1992) *Cell* **68**, 429–440.
9. Manseau, L. J. & Schupbach, T. (1989) *Genes Dev.* **3**, 1437–1452.
10. Hong, C. C. & Hashimoto, C. (1995) *Cell* **82**, 785–794.
11. Seifert, E., Muller-Holtkamp, F., Marcey, D. & Jäckle, H. (1987) *Roux's Arch. Dev. Biol.* **196**, 78–82.
12. Konrad, K. D., Goralski, T. J. & Mahowald, A. P. (1988) *Dev. Biology* **127**, 133–142.
13. DeLotto, R. & Spierer, P. (1986) *Nature (London)* **323**, 688–692.
14. Chasan, R. & Anderson, K. V. (1989) *Cell* **56**, 391–400.
15. Chasan, R., Jin, Y. & Anderson, K. V. (1992) *Development (Cambridge, U.K.)* **115**, 607–616.
16. Smith, C. L. & DeLotto, R. (1994) *Nature (London)* **368**, 548–551.
17. Konsolaki, M. & Schupbach, T. (1998) *Genes Dev.* **12**, 120–131.
18. Anderson, K. V. & Nüsslein-Volhard, C. (1986) in *Gametogenesis and the Early Embryo* (Liss, New York), pp. 177–194.
19. Schüpbach, T. & Wieschaus, E. (1991) *Genetics* **129**, 1119–1136.
20. Lefevre, G., Jr. (1971) *Genetics* **67**, 497–513.
21. Goralski, T. J. (1985) Ph.D. Thesis (Indiana University, Bloomington, IN).
22. Lindsley, D. L. & Zimm, G. G. (1992) *The Genome of Drosophila melanogaster* (Academic, San Diego).
23. Maniatis, T., Hardison, R. C., Lacy, E., Lauer, J., O'Connell, C., Quon, D., Sim, D. K. & Efstratiadis, A. (1978) *Cell* **15**, 687–699.
24. Scott, M. P., Weiner, A. J., Hazelrigg, T. I., Polisky, B. A., Pirrotta, V., Scalenghe, F. & Kaufman, T. C. (1983) *Cell* **35**, 763–776.
25. Maniatis, T., Fritsch, E. F. & Sambrook, J. (1982) *Molecular Cloning: A Laboratory Manual* (Cold Spring Harbor Lab. Press, Plainview, NY).
26. Brown, N. H. & Kafatos, F. C. (1988) *J. Mol. Biol.* **203**, 425–437.
27. Chirgwin, J. M., Przybyla, A. E., MacDonald, R. J. & Rutter, W. J. (1979) *Biochemistry* **18**, 5294–5299.
28. O'Farrell, P. H., Kutter, E. & Nakanishi, M. (1980) *Mol. Gen. Genet.* **179**, 421–435.
29. Sambrook, J., Fritsch, E. F. & Maniatis, T. (1989) *Molecular Cloning: A Laboratory Manual* (Cold Spring Harbor Lab. Press, Plainview, NY), 2nd Ed.
30. Tautz, D. & Pfeifle, C. (1989) *Chromosoma* **98**, 81–85.
31. Bender, W., Spierer, P. & Hogness, D. S. (1983) *J. Mol. Biol.* **168**, 17–33.
32. Mason, E. D., Konrad, K. D., Webb, C. D. & Marsh, J. L. (1994) *Genes Dev.* **8**, 1489–1501.
33. Pirrotta, V. (1988) in *Vectors: A Survey of Molecular Cloning Vectors and Their Uses*, eds. Rodriguez, R. L. & Denhart, D. T. (Butterworths, London), pp. 437–466.
34. Rubin, G. M. & Spradling, A. C. (1982) *Science* **218**, 348–353.
35. Spradling, A. C. & Rubin, G. M. (1982) *Science* **218**, 341–347.
36. Kulkarni, S. J. & Hall, J. C. (1987) *Genetics* **115**, 461–475.
37. Kyte, J. & Doolittle, R. F. (1982) *J. Mol. Biol.* **157**, 105–132.
38. von Heinje, G. (1986) *Nucleic Acids Res.* **14**, 4683–4690.
39. Altschul, S. F., Gish, W., Miller, W., Myers, E. W. & Lipman, D. J. (1990) *J. Mol. Biol.* **215**, 403–410.
40. Greer, J. (1990) *Proteins Struct. Funct. Genet.* **77**, 317–334.
41. Lehmann, R. (1995) *Cell* **83**, 353–356.
42. Morgan, M. M. & Mahowald, A. P. (1996) *Arch. Insect Biochem. Physiol.* **33**, 211–230.
43. Hecht, P. M. & Anderson, K. V. (1992) *Trends. Cell Biol.* **2**, 197–202.
44. Bode, W. & Huber, R. (1978) *FEBS Lett.* **90**, 265–269.
45. Rawlings, N. D. & Barrett, A. J. (1994) *Methods Enzymol.* **244**, 19–61.
46. Mole, J. E., Anderson, J. K., Davison, E. A. & Woods, D. E. (1984) *J. Biol. Chem.* **259**, 3407–3412.
47. Rawlings, N. D. & Barrett, A. J. (1994) *Methods Enzymol.* **244**, 205–218.
48. Kratzschmar, J., Haendler, B., Langer, G., Boidol, W., Bringmann, P., Alagon, A., Donner, P. & Schleuning, W. D. (1991) *Gene* **105**, 229–237.
49. Kjalke, M., Welinder, K. G. & Koch, C. (1993) *J. Immunol.* **151**, 4147–4152.
50. Isackson, P. J., Ullrich, A. & Bradshaw, R. A. (1984) *Biochemistry* **23**, 5997–6002.
51. Smith, C., Giordano, H. & DeLotto, R. (1994) *Genetics* **136**, 1355–1365.